Alzheimers Disease: Erythrocyte 2,3-diphosphoglycerate Content and Circulating ErythropoietinVisa övriga samt affilieringar
2019 (Engelska)Ingår i: Current Alzheimer Research, ISSN 1567-2050, E-ISSN 1875-5828, Vol. 16, nr 9, s. 834-835Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
Background: Alzheimers Disease (AD) features the accumulation of beta-amyloid in erythrocytes. The subsequent red cell damage may well affect their oxygen-carrying capabilities. 2,3-diphosphoglycerate (2,3-DPG) binds to the hemoglobin thereby promoting oxygen release. It is theorized that 2,3-DPG is reduced in AD and that the resulting hypoxia triggers erythropoietin (EPO) release. Methods amp; Objective: To explore this theory, we analyzed red cell 2,3-DPG content and EPO in AD, mild cognitive impairment, and the control group, subjective cognitive impairment. Results: We studied (i) 2,3-DPG in red cells, and (ii) circulating EPO in AD, and both markers were unaffected by dementia. Disturbances of these oxygen-regulatory pathways do not appear to participate in brain hypoxia in AD.
Ort, förlag, år, upplaga, sidor
BENTHAM SCIENCE PUBL LTD , 2019. Vol. 16, nr 9, s. 834-835
Nyckelord [en]
Alzheimer; 2, 3-diphosphoglycerate; erythrocytes; erythropoietin; beta-amyloid; cognitive impairment
Nationell ämneskategori
Neurovetenskaper
Identifikatorer
URN: urn:nbn:se:liu:diva-162087DOI: 10.2174/1567205016666190827120108ISI: 000493721100006PubMedID: 31453787OAI: oai:DiVA.org:liu-162087DiVA, id: diva2:1371319
Anmärkning
Funding Agencies|Hultmans stiftelse for forskning och bistand; Konung Gustaf V och Drottning Victorias stiftelse; Hjarnfonden; Margaretha af Ugglas Stiftelse; Stiftelsen for Gamla Tjanarinnor; Gun and Bertil Stohnes stiftelse
2019-11-192019-11-192019-11-19